Refining post-blinatumomab risk stratification through ultrasensitive-based measurable residual disease assessment

Key Points

• The aim is to enhance risk stratification for patients undergoing treatment with blinatumomab by using ultrasensitive measurable residual disease assessments.
• Utilized ultrasensitive techniques to measure residual disease after blinatumomab treatment.
• Assessed risk stratification based on measurement outcomes in patients.
• Conducted comparative analyses of patient outcomes based on residual disease levels.
• Improved sensitivity in detecting measurable residual disease post-treatment.
• Enhanced risk stratification correlating with patient outcomes after therapy.
• Identification of patients at higher risk of relapse based on residual disease levels.